HomeCompareSARTF vs MAIN

SARTF vs MAIN: Dividend Comparison 2026

SARTF yields 0.37% · MAIN yields 7.09%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MAIN wins by $47.62M in total portfolio value
10 years
SARTF
SARTF
● Live price
0.37%
Share price
$226.33
Annual div
$0.84
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$323.8K
Annual income
$213,389.35
Full SARTF calculator →
MAIN
Main Street Capital Corporation
● Live price
7.09%
Share price
$51.65
Annual div
$3.66
5Y div CAGR
72.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.95M
Annual income
$40,208,699.11
Full MAIN calculator →

Portfolio growth — SARTF vs MAIN

📍 MAIN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSARTFMAIN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SARTF + MAIN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SARTF pays
MAIN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SARTF
Annual income on $10K today (after 15% tax)
$31.55/yr
After 10yr DRIP, annual income (after tax)
$181,380.95/yr
MAIN
Annual income on $10K today (after 15% tax)
$602.32/yr
After 10yr DRIP, annual income (after tax)
$34,177,394.24/yr
At 15% tax rate, MAIN beats the other by $33,996,013.30/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SARTF + MAIN for your $10,000?

SARTF: 50%MAIN: 50%
100% MAIN50/50100% SARTF
Portfolio after 10yr
$24.14M
Annual income
$20,211,044.23/yr
Blended yield
83.74%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MAIN right now

SARTF
Analyst Ratings
1
Buy
1
Sell
Consensus: Buy
Altman Z
2.3
Piotroski
6/9
MAIN
Analyst Ratings
2
Buy
11
Hold
Consensus: Hold
Price Target
$65.25
+26.3% upside vs current
Range: $60.00 — $70.00
Altman Z
1.7
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SARTF buys
0
MAIN buys
0
No recent congressional trades found for SARTF or MAIN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSARTFMAIN
Forward yield0.37%7.09%
Annual dividend / share$0.84$3.66
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%72.7%
Portfolio after 10y$323.8K$47.95M
Annual income after 10y$213,389.35$40,208,699.11
Total dividends collected$294.5K$46.82M
Payment frequencyquarterlymonthly
SectorStockBDC
Analyst consensusBuyHold

Year-by-year: SARTF vs MAIN ($10,000, DRIP)

YearSARTF PortfolioSARTF Income/yrMAIN PortfolioMAIN Income/yrGap
1← crossover$10,774$74.23$12,464$1,223.78$1.7KMAIN
2$11,678$149.49$16,353$2,343.58$4.7KMAIN
3$12,798$302.85$23,105$4,724.42$10.3KMAIN
4$14,314$620.38$36,226$10,256.23$21.9KMAIN
5$16,613$1,296.96$65,426$24,707.64$48.8KMAIN
6$20,590$2,813.57$142,101$68,562.02$121.5KMAIN
7$28,549$6,517.78$388,521$228,799.95$360.0KMAIN
8$47,439$16,892.03$1,397,868$961,169.80$1.35MMAIN
9$103,226$52,465.87$6,884,663$5,313,459.69$6.78MMAIN
10$323,841$213,389.35$47,947,060$40,208,699.11$47.62MMAIN

SARTF vs MAIN: Complete Analysis 2026

SARTFStock

Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products. In addition, the company offers process filtration products; process filtration products; process chromatography products; fluid management products; process analytical technology and data analytics; industrial microbiology systems; water purification systems; weighing systems; pipetting and dispensing systems; OEM systems; and centrifuges. Further, it provides bioprocess development and engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.

Full SARTF Calculator →

MAINBDC

Main Street Capital Corporation is a business development company specializes in equity capital to lower middle market companies. The firm specializing in recapitalizations, management buyouts, refinancing, family estate planning, management buyouts, refinancing, industry consolidation, mature, later stage emerging growth. The firm also provides debt capital to middle market companies for acquisitions, management buyouts, growth financings, recapitalizations and refinancing. The firm seeks to partner with entrepreneurs, business owners and management teams and generally provides one stop financing alternatives within its lower middle market portfolio. It prefers to invest in air freight and logistics, auto components, building products, chemicals, commercial services, computers, construction and engineering, consumer finance, consumer services, electronic equipment, energy equipment and services, financial services, health care equipment, health care providers, hotels, restaurants, and leisure, internet software and services, IT Services, machinery, oil, gas and consumable fuels, paper and forest products, professional and industrial services, road and rail, software, specialty retail, telecommunication, consumer discretionary, energy, materials, technology, and transportation. The firm typically invests in lower middle market companies generally with annual revenues between $5 million and $300 million. It prefers to invest in ranging between $2 million and $75 million in equity investment and enterprise value in ranging between $3 million and $20 million. The firm typically prefers to invest in the range of $5 million and $50 million per transaction in debt investment value and in the range of $1 million and $20 million in annual EBITDA. The firm's middle market debt investments are made in businesses that are generally larger in size than its lower middle market portfolio companies. It takes 5 percent minority and up to 50 percent majority equity investments. Main Street Capital Corporation was founded in 2007 and is based in Houston, Texas with an additional office in Chojnów, Poland.

Full MAIN Calculator →
📬

Get this SARTF vs MAIN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SARTF vs SCHDSARTF vs JEPISARTF vs OSARTF vs KOSARTF vs ARCCSARTF vs HTGCSARTF vs GBDCSARTF vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.